Table 5A.

24 week change in plasma and cerebrospinal fluid cellular stress and inflammatory biomarkers, As Treated^*

Treatment Assignment	Placebo Median (IQR)	Paroxetine only, Median (IQR)	p value	Fluconazole only, Median (IQR)	p value	Paroxetine and Fluconazole, Median (IQR)	p value
	N=4	N=6		N=2		N=7
Cell Stress
Plasma ceramide C16:0 **	−2.77 (−4.53, −1.87)	−0.16 (−1.07, 1.62)	0.178	1.33 (−0.10, 2.75)	0.016	−1.95 (−2.62, 1.19)	0.021
Plasma ceramide	−101.34 (−150.34,	−19.61 (−36.26,	0.020	2.78 (−63.71,	0.004	−25.91 (−104.50,	0.026
C22:0	−13.68)	14.84)**		69.27)		56.79)
Plasma ceramide C24:0	−260.25 (−699.21, 134.64)	−428.25 (−479.72, 152.74)	0.075	465.18 (−248.69, 1179.06)	0.019	−278.65 (−522.54, 1167.59)	0.112
CSF mono−hexosylceramide C24:1	83.05 (−49.45, 222.47)	177.90 (−57.58, 225.21)	0.476	553.86 (364.05, 743.67)	0.010	−19.27 (−122.94, 182.60)	0.650
Inflammation
	N=3	N=5		N=2		N=7
Plasma IL1-α	−18.93, (33.90) 194.37)	−65.82 (−90.36, −2.18)	0.417	−451.48 (−537.54, −365.42)	0.004	−2.53 (−146.45, 140.84)	0.638
	N=3	N=4		N=2		N=7
Plasma CXCL10	518.64 (−24.90), 846.62	−23.58 (60.86, 16.58)	0.005	66.08 (54.57, 77.59)	0.016	2.31 (−163.05, 283.39)	0.009
	N=3	N=5		N=2		N=6
CSF IL-6	−0.03 (−1.25, 2.36)	0.72 (0.63, 1.13)	0.734	−5.99 (−8.00, −3.98)	0.009	−0.59 (−1.01, −0.19)	0.434
	N=3	N=6		N=2		N=3
CSF IL8/CXCL8	−29.79 (−43.16–3.21)	4.23 (−3.76, 8.25)	0.001	−5.48 (−7.51, 3.45)	0.009	2.75 (−5.43, 5.30)	0.011

IL= interleukin

CXCL= C-X-C motif chemokine

^*Models adjust for baseline biomarker level and gender.

^**Negative values indicated less cell stress or inflammation